Halozyme leaps on news of multi-million dollar deals with Bristol-Myers and Roche
US pharma major Bristol-Myers Squibb (NYSE: BMY) has entered into a global collaboration and license agreement to develop its subcutaneously administered immuno-oncology medicines using Halozyme Therapeutics’ (Nasdaq: HALO) ENHANZE drug-delivery technology.
Halozyme’s share price shot up 18.36% to $15.60 in pre-market trading this morning on news of the deal, which coincided with an announcement that Swiss pharma giant Roche (ROG: SIX) plans to use Halozyme’s delivery technology for another target of its own - expanding on their collaboration. This adds a $30 million up-front payment, bringing the deals revealed today to close to a potential $2 billion for Halozyme.
“We are excited to partner with Halozyme to pursue potential new approaches to how our medicines are delivered to patients,” said Murdo Gordon, chief commercial officer, Bristol-Myers Squibb. “Through our work with Halozyme, we hope to improve the patient treatment experience by developing flexible and convenient treatment delivery options.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze